gdc
Multiple Myeloma

Adding to the Therapy Arsenal

Jack Aiello enthusiastically discusses the additions of newer medicines that were FDA approved in 2015, and why patients need to be aware of them.
Video Library – February 5, 2016
Jack Aiello
Patient Advocate
San Jose, CA
Multiple myeloma survivor

I've been diagnosed 21 years with myeloma and there's never been a more exciting year than 2015. We had a drug approved earlier in February, panobinostat, and then three in November. You're right Sam, that there have been an incredible number of new drugs out there, which means patients need to pay attention to them.

It gives us more options as patients because some of the drugs have been developed for brand new treatment categories, which means that proteasome inhibitors and IMiDs that we use and have been effective, it may be that one of the new treatments categories ‑‑ monoclonal antibodies, for example ‑‑ will be added to it and give us a more effective arsenal.

At the same time, these drugs have been approved for certain types of usage. All have been approved for patients who've had previous therapies. Some have been approved to be combined with other drugs.

That's one of the reasons we expect to hear a lot at ASH is trials are still going on with these drugs to expand those approvals, so that they become approved for newly diagnosed patients, or get approved in a maintenance role and such.

Patients need to keep on top of what the approvals mean to them, and I hope their doctor knows all about them as well.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
By Jill Meyer-Lippert, RDH, Amanda Swiecichowski, RN, BSN, CHPN
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
FDA Approvals, News & UpdatesMultiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country